Covalent K-RasG12C Inhibitor Composition for Selective Ras Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing attempts to directly target the K-Ras enzyme with reversible inhibitors have been largely unsuccessful, and there is a need for effective Ras inhibitors and anticancer compounds, particularly those that can target oncogenic mutants such as K-RasG12C without binding to the proto-oncogenic form of the protein.
Innovation Solution
The use of covalent chemistry to develop small molecules that specifically target the K-RasG12C protein by forming a covalent bond with cysteine or aspartate residues, utilizing a Switch 2-Binding Pocket binding moiety connected by chemical linkers to an electrophilic moiety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reversible inhibitors are used to target K-Ras, then the inhibition mechanism is simpler and less toxic, but the binding affinity and effectiveness are insufficient
Solution Approach 1:
The patent changes the chemical bonding parameter from reversible to covalent, transforming the interaction strength and permanence. This allows the inhibitor to form stable, irreversible bonds with the target cysteine residue, dramatically improving inhibition effectiveness and durability while accepting the increased chemical complexity
2Measurement precision
If covalent inhibitors are designed to target specific residues, then the binding specificity increases, but the risk of off-target effects and toxicity increases
Solution Approach 1:
The patent introduces a two-component system where a first moiety provides selective recognition of the target residue through specific molecular interactions, while a second electrophilic moiety forms the covalent bond. This intermediary recognition step acts as a gatekeeper, ensuring that only the correct target is modified before covalent bonding occurs, thereby reducing off-target effects
Solution Approach 2:
The inhibitor design implements local quality by creating distinct functional regions: one region optimized for specific recognition of the target cysteine residue through hydrogen bonding and hydrophobic interactions, and another region optimized for covalent bond formation. This spatial separation of functions allows high specificity without compromising reactivity
3Reliability
If the inhibitor binds to the active site, then the blocking effect is stronger, but the accessibility to the target residue decreases
Solution Approach 1:
The patent transitions from two-dimensional surface binding to three-dimensional covalent attachment. By forming a covalent bond that extends into the protein structure, the inhibitor gains access to residues that are not readily accessible from the surface, effectively utilizing the third dimension to reach buried catalytic residues while maintaining strong binding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively modulate the activity of K-Ras proteins, providing a therapeutic approach for treating diseases associated with K-Ras mutations, such as pancreatic and colorectal cancers, by covalently bonding to specific residues and inhibiting Ras signaling.
Implementation Method 1
The use of covalent chemistry to develop small molecules that specifically target the K-RasG12C protein by forming a covalent bond with cysteine or aspartate residues
Data Source
AI summary
K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.